Summary Of Quarterly Financial Information | QUANTERIX CORPORATION RESTATED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share data) As of March 31, 2023 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 329,354 $ — $ 329,354 Accounts receivable, net of allowance for expected credit losses 22,546 — 22,546 Inventory 17,070 (441) 16,629 Prepaid expenses and other current assets 7,002 (57) 6,945 Total current assets 375,972 (498) 375,474 Restricted cash 2,920 (322) 2,598 Property and equipment, net 19,056 (366) 18,690 Intangible assets, net 7,129 — 7,129 Right-of-use assets 20,891 — 20,891 Other non-current assets 1,345 (407) 938 Total assets $ 427,313 $ (1,593) $ 425,720 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,585 $ — $ 2,585 Accrued compensation and benefits 4,880 531 5,411 Other accrued expenses 4,624 14 4,638 Deferred revenue 10,682 — 10,682 Short-term lease liabilities 3,875 — 3,875 Other current liabilities 291 — 291 Total current liabilities 26,937 545 27,482 Deferred revenue, net of current portion 1,419 — 1,419 Long-term lease liabilities 40,409 — 40,409 Other non-current liabilities 1,216 — 1,216 Total liabilities 69,981 545 70,526 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value per share: Authorized shares: 120,000 shares; Issued and outstanding: 37,424 shares at March 31, 2023. 37 — 37 Additional paid-in capital 768,141 (18) 768,123 Accumulated other comprehensive (loss) income (2,581) 85 (2,496) Accumulated deficit (408,265) (2,205) (410,470) Total stockholders’ equity 357,332 (2,138) 355,194 Total liabilities and stockholders’ equity $ 427,313 $ (1,593) $ 425,720 As of June 30, 2023 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 329,525 $ — $ 329,525 Accounts receivable, net of allowance for expected credit losses 24,423 (54) 24,369 Inventory 18,156 177 18,333 Prepaid expenses and other current assets 6,954 (57) 6,897 Total current assets 379,058 66 379,124 Restricted cash 2,686 (85) 2,601 Property and equipment, net 18,328 (280) 18,048 Intangible assets, net 6,476 — 6,476 Operating lease right-of-use assets 20,380 — 20,380 Other non-current assets 2,282 (645) 1,637 Total assets $ 429,210 $ (944) $ 428,266 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,238 $ — $ 3,238 Accrued compensation and benefits 7,525 650 8,175 Accrued expenses and other current liabilities 6,777 14 6,791 Deferred revenue 10,421 — 10,421 Operating lease liabilities 3,986 — 3,986 Total current liabilities 31,947 664 32,611 Deferred revenue, net of current portion 1,304 — 1,304 Operating lease liabilities, net of current portion 39,378 — 39,378 Other non-current liabilities 1,225 — 1,225 Total liabilities 73,854 664 74,518 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value per share: Authorized shares: 120,000,000 shares; Issued and outstanding: 37,566 shares at June 30, 2023. 37 — 37 Additional paid-in capital 772,473 (1) 772,472 Accumulated other comprehensive loss (2,825) 85 (2,740) Accumulated deficit (414,329) (1,692) (416,021) Total stockholders’ equity 355,356 (1,608) 353,748 Total liabilities and stockholders’ equity $ 429,210 $ (944) $ 428,266 As of September 30, 2023 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 201,261 $ — $ 201,261 Marketable securities 126,449 — 126,449 Accounts receivable, net of allowance for expected credit losses 24,083 — 24,083 Inventory 19,945 912 20,857 Prepaid expenses and other current assets 9,273 (57) 9,216 Total current assets 381,011 855 381,866 Restricted cash 2,647 (45) 2,602 Property and equipment, net 17,517 (230) 17,287 Intangible assets, net 6,003 — 6,003 Operating lease right-of-use assets 19,860 — 19,860 Other non-current assets 2,004 (401) 1,603 Total assets $ 429,042 $ 179 $ 429,221 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,786 $ — $ 4,786 Accrued compensation and benefits 9,775 730 10,505 Accrued expenses and other current liabilities 6,672 14 6,686 Deferred revenue 9,827 — 9,827 Operating lease liabilities 4,093 — 4,093 Total current liabilities 35,153 744 35,897 Deferred revenue, net of current portion 1,126 — 1,126 Operating lease liabilities, net of current portion 38,306 — 38,306 Other non-current liabilities 1,105 — 1,105 Total liabilities 75,690 744 76,434 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value per share: Authorized shares: 120,000,000 shares; Issued and outstanding: 37,839 shares at September 30, 2023. 38 — 38 Additional paid-in capital 778,615 — 778,615 Accumulated other comprehensive loss (3,214) 85 (3,129) Accumulated deficit (422,087) (650) (422,737) Total stockholders’ equity 353,352 (565) 352,787 Total liabilities and stockholders’ equity $ 429,042 $ 179 $ 429,221 Three Months Ended March 31, 2023 As Previously Reported Adjustments As Restated Revenues: Product revenue $ 19,287 $ 73 $ 19,360 Service and other revenue 8,579 (73) 8,506 Collaboration revenue 368 — 368 Grant revenue 222 — 222 Total revenue 28,456 — 28,456 Costs of goods sold: Cost of product revenue 7,033 846 7,879 Cost of service and other revenue 4,497 87 4,584 Total costs of goods sold and services 11,530 933 12,463 Gross profit 16,926 (933) 15,993 Operating expenses: Research and development 4,720 267 4,987 Selling, general and administrative 20,883 (66) 20,817 Other lease costs 776 24 800 Impairment and restructuring (33) — (33) Total operating expenses 26,346 225 26,571 Loss from operations (9,420) (1,158) (10,578) Interest income 3,449 — 3,449 Other income (expense), net 8 (13) (5) Loss before income taxes (5,963) (1,171) (7,134) Income tax expense (140) — (140) Net loss $ (6,103) $ (1,171) $ (7,274) Net loss per common share, basic and diluted $ (0.16) $ (0.03) $ (0.19) Weighted-average common shares outstanding, basic and diluted 37,327 — 37,327 Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Product revenue $ 19,692 $ (143) $ 19,549 $ 38,979 $ (70) $ 38,909 Service revenue 10,552 (82) 10,470 19,131 (155) 18,976 Collaboration and license revenue 629 — 629 997 — 997 Grant revenue 156 — 156 378 — 378 Total revenues 31,029 (225) 30,804 59,485 (225) 59,260 Costs of goods sold and services: Cost of product revenue 7,236 (535) 6,701 14,269 311 14,580 Cost of service and other revenue 4,655 32 4,687 9,152 119 9,271 Total costs of goods sold and services 11,891 (503) 11,388 23,421 430 23,851 Gross profit 19,138 278 19,416 36,064 (655) 35,409 Operating expenses: Research and development 5,946 182 6,128 10,666 449 11,115 Selling, general, and administrative 21,591 (283) 21,308 42,474 (349) 42,125 Other lease costs 1,162 (194) 968 1,938 (170) 1,768 Impairment and restructuring — — — (33) — (33) Total operating expenses 28,699 (295) 28,404 55,045 (70) 54,975 Loss from operations (9,561) 573 (8,988) (18,981) (585) (19,566) Interest income 3,886 — 3,886 7,335 — 7,335 Other expense (154) (60) (214) (146) (73) (219) Loss before income taxes (5,829) 513 (5,316) (11,792) (658) (12,450) Income tax expense (235) — (235) (375) — (375) Net loss $ (6,064) $ 513 $ (5,551) $ (12,167) $ (658) $ (12,825) Net loss per common share, basic and diluted $ (0.16) $ 0.01 $ (0.15) $ (0.33) $ (0.01) $ (0.34) Weighted-average common shares outstanding, basic and diluted 37,494 — 37,494 37,411 — 37,411 Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Product revenue $ 19,660 $ 280 $ 19,940 $ 58,639 $ 210 $ 58,849 Service revenue 10,938 (55) 10,883 30,069 (210) 29,859 Collaboration and license revenue 237 — 237 1,234 — 1,234 Grant revenue 499 — 499 877 — 877 Total revenues 31,334 225 31,559 90,819 — 90,819 Costs of goods sold and services: Cost of product revenue 8,342 (1,133) 7,209 22,611 (822) 21,789 Cost of service and other revenue 5,209 (268) 4,941 14,361 (149) 14,212 Total costs of goods sold and services 13,551 (1,401) 12,150 36,972 (971) 36,001 Gross profit 17,783 1,626 19,409 53,847 971 54,818 Operating expenses: Research and development 7,200 539 7,739 17,866 988 18,854 Selling, general, and administrative 23,595 (45) 23,550 66,069 (394) 65,675 Other lease costs 758 170 928 2,696 — 2,696 Impairment and restructuring — — — (33) — (33) Total operating expenses 31,553 664 32,217 86,598 594 87,192 Loss from operations (13,770) 962 (12,808) (32,751) 377 (32,374) Interest income 4,185 — 4,185 11,520 — 11,520 Other income 2,030 80 2,110 1,884 7 1,891 Loss before income taxes (7,555) 1,042 (6,513) (19,347) 384 (18,963) Income tax expense (203) — (203) (578) — (578) Net loss $ (7,758) $ 1,042 $ (6,716) $ (19,925) $ 384 $ (19,541) Net loss per common share, basic and diluted $ (0.21) $ 0.03 $ (0.18) $ (0.53) $ 0.01 $ (0.52) Weighted-average common shares outstanding, basic and diluted 37,657 — 37,657 37,494 — 37,494 Three Months Ended December 31, 2023 As Previously Reported in the Company's Earnings Release Adjustments As Restated Revenues: Product revenue $ 20,821 $ — $ 20,821 Service and other revenue 10,230 — 10,230 Collaboration revenue 146 — 146 Grant revenue 352 — 352 Total revenue 31,549 — 31,549 Costs of goods sold: Cost of product revenue 10,025 (2,711) 7,314 Cost of service and other revenue 4,725 104 4,829 Total costs of goods sold and services 14,750 (2,607) 12,143 Gross profit 16,799 2,607 19,406 Operating expenses: Research and development 6,991 219 7,210 Selling, general and administrative 24,172 (736) 23,436 Other lease costs 1,016 — 1,016 Impairment and restructuring 1,570 (209) 1,361 Total operating expenses 33,749 (726) 33,023 Loss from operations (16,950) 3,333 (13,617) Interest income 4,319 — 4,319 Other income 363 263 626 Loss before income taxes (12,268) 3,596 (8,672) Income tax expense (141) — (141) Net loss $ (12,409) $ 3,596 $ (8,813) Net loss per common share, basic and diluted $ (0.33) $ 0.10 $ (0.23) Weighted-average common shares outstanding, basic and diluted 37,890 — 37,890 QUANTERIX CORPORATION RESTATED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (amounts in thousands) Three Months Ended March 31, 2023 As Previously Reported Adjustments As Restated Net loss $ (6,103) $ (1,171) $ (7,274) Other comprehensive income, net of tax: Foreign currency translation adjustment 42 — 42 Total other comprehensive income 42 — 42 Comprehensive loss $ (6,061) $ (1,171) $ (7,232) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net loss $ (6,064) $ 513 $ (5,551) $ (12,167) $ (658) $ (12,825) Other comprehensive loss, net of tax: Foreign currency translation adjustment (244) — (244) (202) — (202) Total other comprehensive loss (244) — (244) (202) — (202) Comprehensive loss $ (6,308) $ 513 $ (5,795) $ (12,369) $ (658) $ (13,027) Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net loss $ (7,758) $ 1,042 $ (6,716) $ (19,925) $ 384 $ (19,541) Other comprehensive loss, net of tax: Unrealized losses on marketable securities (241) — (241) (241) — (241) Foreign currency translation adjustment (148) — (148) (350) — (350) Total other comprehensive loss (389) — (389) (591) — (591) Comprehensive loss $ (8,147) $ 1,042 $ (7,105) $ (20,516) $ 384 $ (20,132) QUANTERIX CORPORATION RESTATED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (amounts in thousands) Three Months Ended, March 31, 2023 Common Stock As Previously Reported Shares Amount Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated Total stockholders' equity Balance at December 31, 2022 37,280 $ 37 $ 763,688 $ (2,623) $ (402,162) $ 358,940 Issuance of common stock under stock plans, including tax effects 144 — 551 — — 551 Stock-based compensation expense — — 3,902 — — 3,902 Foreign currency translation adjustment — — — 42 — 42 Net loss — — — — (6,103) (6,103) Balance at March 31, 2023 37,424 $ 37 $ 768,141 $ (2,581) $ (408,265) $ 357,332 Adjustments Balance at December 31, 2022 — $ — $ (59) $ 85 $ (1,034) $ (1,008) Issuance of common stock under stock plans, including tax effects — — — — — — Stock-based compensation expense — — 41 — — 41 Foreign currency translation adjustment — — — — — — Net loss — — — — (1,171) (1,171) Balance at March 31, 2023 — $ — $ (18) $ 85 $ (2,205) $ (2,138) As Restated Balance at December 31, 2022 37,280 $ 37 $ 763,629 $ (2,538) $ (403,196) $ 357,932 Issuance of common stock under stock plans, including tax effects 144 — 551 — — 551 Stock-based compensation expense — — 3,943 — — 3,943 Foreign currency translation adjustment — — — 42 — 42 Net loss — — — — (7,274) (7,274) Balance at March 31, 2023 37,424 $ 37 $ 768,123 $ (2,496) $ (410,470) $ 355,194 Three Months Ended June 30, 2023 Common Stock As Previously Reported Shares Amount Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated Total stockholders' equity Balance at March 31, 2023 37,424 $ 37 $ 768,141 $ (2,581) $ (408,265) $ 357,332 Issuance of common stock under stock plans, including tax effects 142 — 139 — — 139 Stock-based compensation expense — — 4,193 — — 4,193 Foreign currency translation adjustment — — — (244) — (244) Net loss — — — — (6,064) (6,064) Balance at June 30, 2023 37,566 $ 37 $ 772,473 $ (2,825) $ (414,329) $ 355,356 Adjustments Balance at March 31, 2023 — $ — $ (18) $ 85 $ (2,205) $ (2,138) Issuance of common stock under stock plans, including tax effects — — — — — — Stock-based compensation expense — — 17 — — 17 Foreign currency translation adjustment — — — — — — Net loss — — — — 513 513 Balance at June 30, 2023 — $ — $ (1) $ 85 $ (1,692) $ (1,608) As Restated Balance at March 31, 2023 37,424 $ 37 $ 768,123 $ (2,496) $ (410,470) $ 355,194 Issuance of common stock under stock plans, including tax effects 142 — 139 — — 139 Stock-based compensation expense — — 4,210 — — 4,210 Foreign currency translation adjustment — — — (244) — (244) Net loss — — — — (5,551) (5,551) Balance at June 30, 2023 37,566 $ 37 $ 772,472 $ (2,740) $ (416,021) $ 353,748 Six Months Ended June 30, 2023 Common Stock As Previously Reported Shares Amount Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated Total stockholders' equity Balance at December 31, 2022 37,280 $ 37 $ 763,688 $ (2,623) $ (402,162) $ 358,940 Issuance of common stock under stock plans, including tax effects 286 — 690 — — 690 Stock-based compensation expense — — 8,095 — — 8,095 Foreign currency translation adjustment — — — (202) — (202) Net loss — — — — (12,167) (12,167) Balance at June 30, 2023 37,566 $ 37 $ 772,473 $ (2,825) $ (414,329) $ 355,356 Adjustments Balance at December 31, 2022 — $ — $ (59) $ 85 $ (1,034) $ (1,008) Issuance of common stock under stock plans, including tax effects — — — — — — Stock-based compensation expense — — 58 — — 58 Foreign currency translation adjustment — — — — — — Net loss — — — — (658) (658) Balance at June 30, 2023 — $ — $ (1) $ 85 $ (1,692) $ (1,608) As Restated Balance at December 31, 2022 37,280 $ 37 $ 763,629 $ (2,538) $ (403,196) $ 357,932 Issuance of common stock under stock plans, including tax effects 286 — 690 — — 690 Stock-based compensation expense — — 8,153 — — 8,153 Foreign currency translation adjustment — — — (202) — (202) Net loss — — — — (12,825) (12,825) Balance at June 30, 2023 37,566 $ 37 $ 772,472 $ (2,740) $ (416,021) $ 353,748 Three Months Ended, September 30, 2023 Common Stock As Previously Reported Shares Amount Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated Total stockholders' equity Balance at June 30, 2023 37,566 $ 37 $ 772,473 $ (2,825) $ (414,329) $ 355,356 Issuance of common stock under stock plans, including tax effects 273 1 1,799 — — 1,800 Stock-based compensation expense — — 4,343 — — 4,343 Unrealized loss on marketable securities, net of tax — — — (241) — (241) Foreign currency translation adjustment — — — (148) — (148) Net loss — — — — (7,758) (7,758) Balance at September 30, 2023 37,839 $ 38 $ 778,615 $ (3,214) $ (422,087) $ 353,352 Adjustments Balance at June 30, 2023 — $ — $ (1) $ 85 $ (1,692) $ (1,608) Issuance of common stock under stock plans, including tax effects — — — — — — Stock-based compensation expense — — 1 — — 1 Unrealized loss on marketable securities, net of tax — — — — — — Foreign currency translation adjustment — — — — — — Net loss — — — — 1,042 1,042 Balance at September 30, 2023 — $ — $ — $ 85 $ (650) $ (565) As Restated Balance at June 30, 2023 37,566 $ 37 $ 772,472 $ (2,740) $ (416,021) $ 353,748 Issuance of common stock under stock plans, including tax effects 273 1 1,799 — — 1,800 Stock-based compensation expense — — 4,344 — — 4,344 Unrealized loss on marketable securities, net of tax — — — (241) — (241) Foreign currency translation adjustment — — — (148) — (148) Net loss — — — — (6,716) (6,716) Balance at September 30, 2023 37,839 $ 38 $ 778,615 $ (3,129) $ (422,737) $ 352,787 Nine Months Ended, September 30, 2023 Common Stock As Previously Reported Shares Amount Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated Total stockholders' equity Balance at December 31, 2022 37,280 $ 37 $ 763,688 $ (2,623) $ (402,162) $ 358,940 Issuance of common stock under stock plans, including tax effects 559 1 2,489 — — 2,490 Stock-based compensation expense — — 12,438 — — 12,438 Unrealized loss on marketable securities, net of tax — — — (241) — (241) Foreign currency translation adjustment — — — (350) — (350) Net loss — — — — (19,925) (19,925) Balance at September 30, 2023 37,839 $ 38 $ 778,615 $ (3,214) $ (422,087) $ 353,352 Adjustments Balance at December 31, 2022 — $ — $ (59) $ 85 $ (1,034) $ (1,008) Issuance of common stock under stock plans, including tax effects — — — — — — Stock-based compensation expense — — 59 — — 59 Unrealized loss on marketable securities, net of tax — — — — — — Foreign currency translation adjustment — — — — — — Net loss — — — — 384 384 Balance at September 30, 2023 — $ — $ — $ 85 $ (650) $ (565) As Restated Balance at December 31, 2022 37,280 $ 37 $ 763,629 $ (2,538) $ (403,196) $ 357,932 Issuance of common stock under stock plans, including tax effects 559 1 2,489 — — 2,490 Stock-based compensation expense — — 12,497 — — 12,497 Unrealized loss on marketable securities, net of tax — — — (241) — (241) Foreign currency translation adjustment — — — (350) — (350) Net loss — — — — (19,541) (19,541) Balance at September 30, 2023 37,839 $ 38 $ 778,615 $ (3,129) $ (422,737) $ 352,787 QUANTERIX CORPORATION RESTATED CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in thousands) Three Months Ended March 31, 2023 As Previously Reported Adjustments As Restated Operating activities: Net loss $ (6,103) $ (1,171) $ (7,274) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 1,439 15 1,454 Credit losses on accounts receivable 178 — 178 Non-cash operating lease expense 334 — 334 Stock-based compensation expense 3,902 41 3,943 Deferred taxes 270 — 270 Changes in operating assets and liabilities: Accounts receivable (3,741) — (3,741) Inventory (89) 619 530 Prepaid expenses and other assets (422) — (422) Other non-current assets (33) — (33) Accounts payable (1,271) — (1,271) Accrued compensation and benefits, other accrued expenses and other current liabilities (5,983) 174 (5,809) Deferred revenue 2,041 — 2,041 Operating lease liabilities 179 — 179 Other non-current liabilities (203) — (203) Net cash used in operating activities (9,502) (322) (9,824) Investing activities Purchases of property and equipment (136) — (136) Net cash used in investing activities (136) — (136) Financing activities Proceeds from stock options exercised 13 — 13 Proceeds from ESPP purchase 551 — 551 Payments for employee taxes on units withheld (13) — (13) Net cash provided by financing activities 551 — 551 Net decrease in cash, cash equivalents and restricted cash (9,087) (322) (9,409) Effect of foreign currency exchange rate on cash 24 — 24 Cash, cash equivalents and restricted cash at beginning of period 341,337 — 341,337 Cash, cash equivalents and restricted cash at end of period $ 332,274 $ (322) $ 331,952 Supplemental disclosure of cash flow information: Cash paid for income taxes $ 246 $ — $ 246 Noncash transactions: Purchases of property and equipment included in accounts payable and accrued expenses $ 147 $ — $ 147 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 329,354 $ — $ 329,354 Restricted cash $ 2,920 $ (322) $ 2,598 Total cash, cash equivalents, and restricted cash $ 332,274 $ (322) $ 331,952 Six Months Ended June 30, 2023 As Previously Reported Adjustments As Restated Cash flows from operating activities: Net loss $ (12,167) $ (658) $ (12,825) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 2,845 38 2,883 Credit losses on accounts receivable 324 — 324 Operating lease right-of-use asset amortization 1,002 — 1,002 Stock-based compensation expense 8,095 58 8,153 Other operating activity 548 54 602 Loss on disposal of fixed assets Impairment — 54 54 Changes in assets and liabilities: Accounts receivable (5,750) — (5,750) Inventory (1,181) 1 (1,180) Prepaid expenses and other current assets (527) — (527) Other non-current assets (965) 258 (707) Accounts payable (631) — (631) Accrued compensation and benefits, accrued expenses, and other current liabilities (1,326) 273 (1,053) Deferred revenue 1,666 — 1,666 Operating lease liabilities (730) — (730) Other non-current liabilities (72) — (72) Net cash used in operating activities (8,869) 78 (8,791) Cash flows from investing activities: Purchases of property and equipment (784) (163) (947) Net cash used in investing activities (784) (163) (947) Cash flows from financing activities: Proceeds from common stock issued under stock plans 777 — 777 Payments for employee taxes withheld on stock-based compensation awards (87) — (87) Net cash provided by financing activities 690 — 690 Net decrease in cash, cash equivalents, and restricted cash (8,963) (85) (9,048) Effect of exchange rate changes on cash, cash equivalents, and restricted cash (163) — (163) Cash, cash equivalents, and restricted cash at beginning of period 341,337 — 341,337 Cash, cash equivalents, and restricted cash at end of period $ 332,211 $ (85) $ 332,126 Supplemental disclosure of cash flow information: Cash paid for taxes $ 502 $ — $ 502 Shares received as consideration under product sales agreement (Note 4, 7) $ 1,000 $ — $ 1,000 Nine Months Ended September 30, 2023 As Previously Reported Adjustments As Restated Cash flows from operating activities: Net loss $ (19,925) $ 384 $ (19,541) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense 4,788 55 4,843 Credit losses on accounts receivable 311 — 311 Foreign currency losses 359 — 359 Unrealized losses on marketable securities (241) — (241) Amortization of (discount) premium on marketable securities (1,249) — (1,249) Operating lease right-of-use asset amortization 1,518 — 1,518 Stock-based compensation expense 12,438 59 12,497 Impairment — 130 130 Deferred income taxes 242 — 242 Loss on disposal of fixed assets 46 — 46 Accounts receivable (5,615) — (5,615) Inventory (2,966) (734) (3,700) Prepaid expenses and other current assets (2,829) — (2,829) Other non-current assets (716) 14 (702) Accounts payable 948 — 948 Accrued compensation and benefits, accrued expenses, and other current liabilities 876 353 1,229 Deferred revenue 894 — 894 Operating lease liabilities (1,690) — (1,690) Other non-current liabilities (107) — (107) Net cash used in operating activities (12,918) 261 (12,657) Cash flows from investing activities: Purchases of marketable securities (125,200) — (125,200) Proceeds from marketable debt securities Purchases of property and equipment (1,572) (306) (1,878) Proceeds from RADx grant on assets purchased Net cash used in investing activities (126,772) (306) (127,078) Cash flows from financing activities: Proceeds from common stock issued under stock plans 2,632 — 2,632 Payments for employee taxes withheld on stock-based compensation awards (142) — (142) Net cash provided by financing activities 2,490 — 2,490 Net decrease in cash, cash equivalents, and restricted cash (137,200) (45) (137,245) Effect of exchange rate changes on cash, cash equivalents, and restricted cash (229) — (229) Cash, cash equivalents, and restricted cash at beginning of period 341,337 — 341,337 Cash, cash equivalents, and restricted cash at end of period $ 203,908 $ (45) $ 203,863 Supplemental disclosure of cash flow information: Cash paid for taxes $ 719 $ — $ 719 Shares received as consideration under product sales agreement (Note 4, 7) $ 775 $ — $ 775 QUANTERIX CORPORATION RESTATED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share data) As of March 31, 2022 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 374,317 $ 226 $ 374,543 Accounts receivable, net of allowance for expected credit losses 22,616 — 22,616 Inventory 22,669 1,757 24,426 Prepaid expenses and other current assets 14,104 (226) 13,878 Total current assets 433,706 1,757 435,463 Restricted cash 2,577 — 2,577 Property and equipment, net 19,683 (44) 19,639 Intangible assets, net 9,692 — 9,692 Goodwill 9,323 — 9,323 Right-of-use assets 29,298 617 29,915 Other non-current assets 378 (300) 78 Total assets $ 504,657 $ 2,030 $ 506,687 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,262 $ (75) $ 4,187 Accrued compensation and benefits 8,139 57 8,196 Other accrued expenses 8,024 — 8,024 Deferred revenue 9,194 — 9,194 Short term lease liabilities 1,886 — 1,886 Other current liabilities 268 — 268 Total current liabilities 31,773 (18) 31,755 Deferred revenue, net of current portion 1,222 — 1,222 Long term lease liabilities 43,563 — 43,563 Other non-current liabilities 1,691 — 1,691 Total liabilities 78,249 (18) 78,231 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value: Authorized shares: 120,000 shares; Issued and outstanding: 36,899 shares at March 31, 2022. 37 — 37 Additional paid-in capital 750,742 (25) 750,717 Accumulated other comprehensive (loss) income (756) — (756) Accumulated deficit (323,615) 2,073 (321,542) Total stockholders’ equity 426,408 2,048 428,456 Total liabilities and stockholders’ equity $ 504,657 $ 2,030 $ 506,687 As of June 30, 2022 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 361,293 $ 258 $ 361,551 Accounts receivable, net of allowance for expected credit losses 19,683 — 19,683 Inventory 21,985 700 22,685 Prepaid expenses and other current assets 10,237 (258) 9,979 Total current assets 413,198 700 413,898 Restricted cash 2,594 — 2,594 Property and equipment, net 22,295 (319) 21,976 Intangible assets, net 8,527 — 8,527 Goodwill 8,675 — 8,675 Right-of-use assets 32,935 — 32,935 Other non-current assets 377 (300) 77 Total assets $ 488,601 $ 81 $ 488,682 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,983 $ (75) $ 5,908 Accrued compensation and benefits 10,638 139 10,777 Other accrued expenses 4,799 — 4,799 Deferred revenue 12,157 — 12,157 Short term lease liabilities 2,696 — 2,696 Other current liabilities 396 — 396 Total current liabilities 36,669 64 36,733 Deferred revenue, net of current portion 1,531 — 1,531 Long term lease liabilities 43,135 — 43,135 Other non-current liabilities 1,810 — 1,810 Total liabilities 83,145 64 83,209 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value: Authorized shares: 120,000 shares; Issued and outstanding: 36,975 shares at June 30, 2022. 37 — 37 Additional paid-in capital 756,139 (52) 756,087 Accumulated other comprehensive (loss) income (2,203) — (2,203) Accumulated deficit (348,517) 69 (348,448) Total stockholders’ equity 405,456 17 405,473 Total liabilities and stockholders’ equity $ 488,601 $ 81 $ 488,682 As of September 30, 2022 As Previously Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 343,743 $ — $ 343,743 Accounts receivable, net of allowance for expected credit losses 18,330 — 18,330 Inventory 18,236 (192) 18,044 Prepaid expenses and other current assets 6,475 (400) 6,075 Total current assets 386,784 (592) 386,192 Restricted cash 2,596 — 2,596 Property and equipment, net 21,441 (246) 21,195 Intangible assets, net 7,511 — 7,511 Right-of-use assets 27,165 — 27,165 Other non-current assets 1,200 (290) 910 Total assets $ 446,697 $ (1,128) $ 445,569 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,106 $ — $ 2,106 Accrued compensation and benefits 10,503 257 10,760 Other accrued expenses 5,951 90 6,041 Deferred revenue 8,976 — 8,976 Short-term lease liabilities 767 — 767 Other current liabilities 268 — 268 Total current liabilities 28,571 347 28,918 Deferred revenue, net of current portion 1,591 — 1,591 Long-term lease liabilities 42,196 — 42,196 Other non-current liabilities 1,570 — 1,570 Total liabilities 73,928 347 74,275 Commitments and contingencies (Note 16) Stockholders’ equity: Common stock, $0.001 par value: Authorized shares: 120,000 shares; Issued and outstanding: 37,094 shares at September 30, 2022. 37 — 37 Additional paid-in capital 759,312 (58) 759,254 Accumulated other comprehensive (loss) income (2,999) — (2,999) Accumulated deficit (383,581) (1,417) (384,998) Total stockholders’ equity 372,769 (1,475) 371,294 Total liabilities and stockholders’ equity $ 446,697 $ (1,128) $ 445,569 QUANTERIX CORPORATION RESTATED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data) Three Months Ended March 31, 2022 As Previously Reported Adjustments As Restated Revenues: Product revenue $ 20,656 $ — $ 20,656 Service and other revenue 8,810 — 8,810 Collaboration revenue 86 — 86 Total revenue 29,552 — 29,552 Costs of goods sold: Cost of product revenue 10,746 711 11,457 Cost of service and other revenue 4,247 (249) 3,998 Total costs of goods sold and services 14,993 462 15,455 Gross profit 14,559 (462) 14,097 Operating expenses: Research and development 7,034 (154) 6,880 Selling, general and administrative 25,712 (541) 25,171 Total operating expenses 32,746 (695) 32,051 Loss from operations (18,187) 233 (17,954) Interest income 52 — 52 Other expense (217) — (217) Loss before income taxes (18,352) 233 (18,119) Income tax benefit 199 — 199 Net loss $ (18,153) $ 233 $ (17,920) Net loss per common share, basic and diluted $ (0.49) $ — $ (0.49) Weighted-average common shares outstanding, basic and diluted 36,851 — 36,851 Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Product revenue $ 14,785 $ — $ 14,785 $ 35,441 $ — $ 35,441 Service and other revenue 8,548 — 8,548 17,358 — 17,358 Collaboration revenue 92 — 92 178 — 178 Grant revenue 75 — 75 75 — 75 Total revenue 23,500 — 23,500 53,052 — 53,052 Costs of goods sold: Cost of product revenue 9,921 625 10,546 20,667 1,336 22,003 Cost of service and other revenue 4,868 (231) 4,637 9,115 (480) 8,635 Total costs of goods sold and services 14,789 394 15,183 29,782 856 30,638 Gross profit 8,711 (394) 8,317 23,270 (856) 22,414 Operating expenses: Research and development 6,625 632 7,257 13,659 478 14,137 Selling, general and administrative 27,045 771 27,816 52,757 230 52,987 Impairment and restructuring — 207 207 — 207 207 Total operating expenses 33,670 1,610 35,280 66,416 915 67,331 Loss from operations (24,959) (2,004) (26,963) (43,146) (1,771) (44,917) Interest income 552 — 552 604 — 604 Other expense (358) — (358) (575) — (575) Loss before income taxes (24,765) (2,004) (26,769) (43,117) (1,771) (44,888) Income tax (expense) benefit (137) — (137) 62 — 62 Net loss $ (24,902) $ (2,004) $ (26,906) $ (43,055) $ (1,771) $ (44,826) Net loss per common share, basic and diluted $ (0.67) $ (0.06) $ (0.73) $ (1.17) $ (0.05) $ (1.22) Weighted-average common shares outstanding, basic and diluted 36,922 — 36,922 36,887 — 36,887 Three Months Ended September 30, 2022 Nine Months Ended September 30 |